Morgan Stanley Blueprint Medicines Corp Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Morgan Stanley holds 1,031,170 shares of BPMC stock, worth $133 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,031,170
Previous 568,699
81.32%
Holding current value
$133 Million
Previous $50.3 Million
162.59%
% of portfolio
0.01%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding BPMC
# of Institutions
389Shares Held
66.9MCall Options Held
973KPut Options Held
1.54M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
Jpmorgan Chase & CO New York, NY2.51MShares$324 Million0.02% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...